Back to Breast Cancer

Breast Cancer: patient access summary

A printable summary of what is publicly known about access to treatment for Breast Cancer in Australia: PBS subsidy, Australian trial recruitment, and where the gaps are. Nothing here is new information; it is the same reviewed data as the Breast Cancer page, laid out to print. Not medical advice.

Access in Australia

Can you access treatment for Breast Cancer in Australia right now? Here's what's publicly known.

Information on this site does not constitute medical advice. Data is sourced from publicly available government registries. Always consult your doctor before making any health decisions. Trial status should be verified directly with the trial site.

Clinical trial activity

Counted from the nightly snapshot of the full public trial registry data Voxsanity holds for Breast Cancer.
Trials on record 6,171 This is every trial tagged to this condition at any stage whose registry record agrees it is for this condition, except those withdrawn before starting or terminated early. Most are completed rather than ongoing, so this is a measure of research history, not of current activity. It is also smaller than the sitewide "trials tracked" figure, which does include withdrawn and terminated trials.
Recruiting now 1,042 This counts only trials whose registry status is "Recruiting" and whose registry record agrees they are for this condition. Trials listed as not yet recruiting or enrolling by invitation are excluded, so this understates how many may open to new participants soon.
Recruiting with an AU site 39 This counts trials counted under "Recruiting now" that list at least one Australian site. A site being listed does not mean it is currently enrolling, and Australian trials registered only on ANZCTR are not counted yet, so this understates local availability.
Phase 3 trials 101 This counts trials counted under "Recruiting now" that are at Phase 3.

The trial catalogue is checked nightly, but individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Trials recruiting at Australian sites

Why this list is shorter than "Trials on record". Of the 6,171 trials on record for Breast Cancer, 1,424 are listed on Voxsanity. The list carries trials we can show a plain English summary for: every trial open or about to open to new participants, plus concluded trials that have published their results. The great majority of the difference is research that finished without publishing a results summary, so there is nothing to read and nothing to join. A smaller part is trials that are open now but whose plain English summary has not been written yet. Nothing is being withheld: the larger figure counts research history, this list counts what is useful to read today.

39 of them are recruiting and list at least one Australian site. A listed site is not proof it is enrolling today; confirm with the trial's own contacts before relying on it.

Registry ID Phase Sponsor Status
NCT04585750 Phase 2 PMV Pharmaceuticals, Inc Recruiting
NCT04802759 Phase 2 Hoffmann-La Roche Recruiting
NCT05086692 Phase 2 Medicenna Therapeutics, Inc. Recruiting
NCT05184790 Not Applicable University of Sydney Recruiting
NCT05216432 Phase 1 Relay Therapeutics, Inc. Recruiting
NCT05350722 Not Applicable Amsterdam UMC, location VUmc Recruiting
NCT05417516 Phase 3 Ontario Clinical Oncology Group (OCOG) Recruiting
NCT05508906 Phase 1 Olema Pharmaceuticals, Inc. Recruiting
NCT05592938 Not Applicable University Health Network, Toronto Recruiting
NCT05633654 Phase 3 Gilead Sciences Recruiting
NCT05706129 Phase 2 Lumara Bio Oncologics GmbH Recruiting
NCT05774951 Phase 3 AstraZeneca Recruiting
NCT05827081 Phase 3 Novartis Pharmaceuticals Recruiting
NCT05950945 Phase 3 Daiichi Sankyo Recruiting
NCT06022029 Phase 1 OncoNano Medicine, Inc. Recruiting
NCT06065748 Phase 3 Hoffmann-La Roche Recruiting
NCT06103864 Phase 3 AstraZeneca Recruiting
NCT06172478 Phase 2 Daiichi Sankyo Recruiting
NCT06242470 Phase 1 MacroGenics Recruiting
NCT06337084 Phase 1 Monopar Therapeutics Recruiting
NCT06380751 Phase 3 AstraZeneca Recruiting
NCT06393374 Phase 3 Merck Sharp & Dohme LLC Recruiting
NCT06465069 Phase 1 Eli Lilly and Company Recruiting
NCT06617169 Phase 1 Monopar Therapeutics Recruiting
NCT06757634 Phase 3 Celcuity Inc Recruiting
NCT06841354 Phase 3 Merck Sharp & Dohme LLC Recruiting
NCT06910657 Phase 1 ViroMissile, Inc. Recruiting
NCT06966700 Phase 3 Merck Sharp & Dohme LLC Recruiting
NCT06982521 Phase 3 Relay Therapeutics, Inc. Recruiting
NCT07060807 Phase 3 Merck Sharp & Dohme LLC Recruiting
NCT07062965 Phase 3 Pfizer Recruiting
NCT07085767 Phase 3 Olema Pharmaceuticals, Inc. Recruiting
NCT07222267 Phase 1 BeOne Medicines Recruiting
NCT07341737 Phase 2 Second Life Therapeutics Recruiting
NCT07358377 Phase 1 Atridia Pty Ltd. Recruiting
NCT07369505 Phase 1 SAPU NANO (US) LLC Recruiting
NCT07413939 Phase 3 Hoffmann-La Roche Recruiting
NCT07492641 Phase 3 BeOne Medicines Recruiting
NCT07660055 Phase 1 Novartis Pharmaceuticals Recruiting

Full eligibility for each trial is at voxsanity.com.au/trials/<registry ID>/, and on the registry itself: clinicaltrials.gov, or isrctn.com for an ISRCTN ID.

PBS-subsidised medicines

Updated nightly, except PBS listing data, which is updated monthly because the PBS publishes a new Schedule once a month.

These medicines are listed on the Pharmaceutical Benefits Scheme (PBS) for the specific indications shown. A listing does not mean a medicine is right for you; your doctor decides what is appropriate. The Government price column is the PBS-determined price the Government pays the pharmacy for the item — it is not what you pay at the counter. Most patients pay only the standard co-payment, up to AU$25.00 per script (general) or AU$7.70 (concession or Safety Net) in 2026, with the Australian Government subsidising the rest. Confirm the current amount with your pharmacist.

Medicine Brand(s) Listed for Government pricenot what you pay Authority
Abemaciclib Verzenio breast cancer Locally advanced or metastatic AU$3883.46 Authority required
capivasertib Truqap breast cancer Locally advanced or metastatic AU$8397 Authority required
Eribulin Halaven breast cancer Locally advanced or metastatic AU$162.45 Streamlined authority
Fulvestrant Fulvestrant Sandoz breast cancer Locally advanced or metastatic AU$134.6 Streamlined authority
Palbociclib Ibrance breast cancer Locally advanced or metastatic AU$3495.12 Authority required
Ribociclib Kisqali breast cancer Locally advanced or metastatic AU$1595.5 Authority required
Anastrozole APO-Anastrozole Breast cancer AU$6.15 Restricted benefit
Exemestane Aromasin Breast cancer AU$35.19 Restricted benefit
Goserelin Zoladex Implant Breast cancer AU$181.32 Restricted benefit
Letrozole Femara 2.5 mg Breast cancer AU$7.55 Restricted benefit
Medroxyprogesterone Provera Breast cancer AU$67.83 Restricted benefit
Tamoxifen Genox 20, Nolvadex-D Breast cancer AU$4.4 Restricted benefit
Lapatinib Tykerb HER2 positive breast cancer Metastatic (Stage IV) AU$1023.94 Authority required
Pertuzumab Perjeta HER2 positive breast cancer Metastatic (Stage IV) AU$2772.81 Authority required
Trastuzumab Herceptin SC, Ogivri HER2 positive breast cancer Metastatic (Stage IV) AU$105.18 Streamlined authority
Trastuzumab deruxtecan Enhertu HER2 positive breast cancer Metastatic (Stage IV) AU$2493.06 Authority required
Trastuzumab emtansine Kadcyla HER2 positive breast cancer Metastatic (Stage IV) AU$1482.83 Authority required
Abemaciclib Verzenio breast cancer Early AU$3883.46 Authority required
Olaparib Lynparza breast cancer Early AU$3234.75 Authority required
Ribociclib Kisqali breast cancer Early AU$1595.5 Authority required
Pertuzumab Perjeta HER2 positive breast cancer Early AU$2772.81 Authority required
Trastuzumab Herceptin SC, Ogivri HER2 positive breast cancer Early AU$105.18 Streamlined authority
Trastuzumab emtansine Kadcyla HER2 positive breast cancer Early AU$1482.83 Authority required
nanoparticle albumin-bound paclitaxel nab-PACLITAXEL JUNO breast cancer Metastatic AU$217.82 Streamlined authority
Olaparib Lynparza breast cancer Metastatic AU$3234.75 Authority required
Everolimus Afinitor breast cancer Metastatic (Stage IV) AU$796.7 Authority required
Exemestane Aromasin breast cancer Metastatic (Stage IV) AU$35.19 Restricted benefit
Zoledronic acid DEZTRON Adjuvant management of breast cancer AU$45.72 Streamlined authority
Vinorelbine Velabine breast cancer Advanced AU$38.18 Authority required
nanoparticle albumin-bound paclitaxel nab-PACLITAXEL JUNO HER2 positive breast cancer AU$217.82 Streamlined authority
Trastuzumab deruxtecan Enhertu HER2-low breast cancer Unresectable and/or metastatic AU$2493.06 Authority required
Tamoxifen Nolvadex-D Reduction of breast cancer risk AU$4.4 Restricted benefit
Pembrolizumab Keytruda triple negative breast cancer Recurrent, unresectable or metastatic AU$3632.56 Streamlined authority
Pembrolizumab Keytruda triple negative breast cancer Stage II or Stage III AU$3632.56 Streamlined authority
Sacituzumab govitecan Trodelvy Unresectable locally advanced or metastatic triple-negative breast cancer AU$1484.59 Streamlined authority

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.

What this summary does not cover

  • Australian registration dates. Voxsanity holds no TGA registration record for any medicine, so no Australian registration date appears here or anywhere on this site. The TGA's own Australian Register of Therapeutic Goods (tga.gov.au/resources/artg) is the authoritative place to check. Where a medicine is on the PBS it must already be registered for supply in Australia, because a PBS listing cannot happen before that: that is read from the PBS, not from the TGA.
  • Access outside the PBS and outside a trial. Where a medicine is not registered or not available through a trial, the TGA Special Access Scheme may allow a doctor to apply for access for an individual patient. A plain English explainer is at voxsanity.com.au/sas-navigator/.
  • Whether any of it is appropriate. Nothing on this sheet is a recommendation. A medicine being subsidised, or a trial recruiting nearby, says nothing about whether either suits a particular person. That is a clinical judgement this sheet cannot make.

Not medical advice. Voxsanity republishes public government health data in plain English and does not provide medical advice. Always consult a qualified health professional before making any health decision. Trial status should be verified directly with the trial site. Sources: ClinicalTrials.gov and other public trial registries, and the Pharmaceutical Benefits Scheme.